Mesoblast (MESO) Stock Forecast, Price & News

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mesoblast in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" MESO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MESO, but not buy additional shares or sell existing shares.
View MESO analyst ratings or view top-rated stocks.

6 brokerages have issued 1-year target prices for Mesoblast's shares. Their MESO share price forecasts range from $1.50 to $17.00. On average, they expect the company's share price to reach $7.13 in the next year. This suggests a possible upside of 493.8% from the stock's current price.
View analysts price targets for MESO or view top-rated stocks among Wall Street analysts.

Mesoblast's stock was trading at $2.91 at the start of the year. Since then, MESO stock has decreased by 58.8% and is now trading at $1.20.
View the best growth stocks for 2023 here.

Mesoblast saw a decrease in short interest during the month of September. As of September 15th, there was short interest totaling 941,200 shares, a decrease of 15.2% from the August 31st total of 1,110,000 shares. Based on an average trading volume of 522,000 shares, the days-to-cover ratio is presently 1.8 days.
View Mesoblast's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 28th 2023.
View our MESO earnings forecast.

Mesoblast Limited (NASDAQ:MESO) released its quarterly earnings results on Wednesday, August, 30th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.03. The business had revenue of $2.14 million for the quarter, compared to analyst estimates of $2 million. Mesoblast had a negative trailing twelve-month return on equity of 16.32% and a negative net margin of 1,061.43%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Mesoblast investors own include Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Exelixis (EXEL), CRISPR Therapeutics (CRSP), Novavax (NVAX), Micron Technology (MU), Vaxart (VXRT) and AbbVie (ABBV).

(MESO) raised $69 million in an initial public offering on Friday, November 13th 2015. The company issued 5,700,000 shares at $12.10 per share. J.P. Morgan and Credit Suisse served as the underwriters for the IPO and Maxim Group and Ladenburg Thalmann were co-managers.

Mesoblast trades on the NASDAQ under the ticker symbol "MESO."

Shares of MESO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MESO stock can currently be purchased for approximately $1.20.

Mesoblast (NASDAQ:MESO) has a market capitalization of $195.41 million and generates $7.50 million in revenue each year. The company earns $-81,890,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis.

Mesoblast's mailing address is LEVEL 38 55 COLLINS STREET, MELBOURNE C3, 3000. The official website for the company is www.mesoblast.com. The company can be reached via phone at (139) 639-6036, via email at schond.greenway@mesoblast.com, or via fax at 61-3-9639-6030.